HK Stock Market Move | CITIC FAMC(02799) continues to rise by over 6%, expected annual net profit to increase more than four times, recently completed the transfer of financial license worth 12 billion yuan.
China CITIC Financial Assets (02799) continues to rise by over 6%, as of press time, up by 4.76% to HK$0.66, with a turnover of HK$10.4998 million.
CITIC FAMC (02799) rose more than 6% again, up 4.76% as of press time, at HK$0.66, with a turnover of HK$104.98 million.
On the news front, on January 16, CITIC FAMC released a profit forecast, stating that based on preliminary accounting data, the net profit attributable to the company's shareholders for the year 2024 is expected to be between 9 billion and 10 billion yuan, an increase of 410% to 466% year-on-year. It is reported that the net profit attributable to the company's shareholders for the year 2023 was 1.766 billion yuan.
It is worth noting that CITIC FAMC has recently completed the transfer of 60% of the shares of Huarong Financial Leasing Limited to Citic Group. After this transaction is completed, CITIC FAMC will hold 2.503 billion shares of Huarong Finance Leasing, accounting for 19.92%, and the latter will become an associated company of the company, no longer a subsidiary of the consolidated financial statements.
Related Articles

HK Stock Market Move | JINGCHENG MAC (00187) increased by over 5%, affiliated with Beijing Bawei to support the world's first tower-type solar thermal replacement project for ultra-heavy oil extraction being put into operation.

Innovative drug blockbuster! Arvinas (ARVN.US) collaborates with Pfizer Inc. (PFE.US) to advance the third-party commercialization of "breast cancer ER degrader."

BOCOM INTL: Slight differences between domestic and foreign capital in the industry fluctuations, seizing the opportunity to layout the undervalued high-quality assets in the innovative pharmaceutical industry chain.
HK Stock Market Move | JINGCHENG MAC (00187) increased by over 5%, affiliated with Beijing Bawei to support the world's first tower-type solar thermal replacement project for ultra-heavy oil extraction being put into operation.

Innovative drug blockbuster! Arvinas (ARVN.US) collaborates with Pfizer Inc. (PFE.US) to advance the third-party commercialization of "breast cancer ER degrader."

BOCOM INTL: Slight differences between domestic and foreign capital in the industry fluctuations, seizing the opportunity to layout the undervalued high-quality assets in the innovative pharmaceutical industry chain.
